74816
document
Prospective controlled study of androgen therapy in the anemia of chronic renal disease : effects on iron kinetics . Ferrokinetic and RBC mass determinations were made at 3-month intervals in iron-replete hemodialysis patients randomized to a control group or to nandrolone decanoate therapy . After 3 months , RBC mass increased in two of 4 androgen-treated patients . Erythron iron turnover , an index of RBC production , increased in the one responder studied but not in the two nonresponders . Similarly , in a fifth subject , who was not restudied until 6 months of androgen therapy were completed , an increase in RBC mass was associated with an increase in erythron iron turnover . However , between 3 and 6 months , RBC mass increased in all 4 androgen-treated patients studied even though erythron iron turnovers remained unchanged and dialysis-associated blood losses did not decrease . Thus , at least two androgen-treated patients had increases in RBC mass without ever increasing their erythron iron turnover . Two of three control subjects also had increased erythron iron turnovers , which in one case was related to increased dialysis-associated blood losses . Changes in RBC mass were not consistently paralleled by changes in Hb . These findings suggest that increases in RBC mass during nandrolone decanoate therapy result from two mechanisms : increased erythropoiesis ( shown by simultaneous increases in RBC mass and erythron iron turnover ) and increased RBC survival ( indirectly shown by increases in RBC mass without increases in erythron iron turnover ) . The importance of control groups , RBC mass determinations and the monitoring of dialysis-associated blood losses in studying the effects of androgens on erythropoiesis in chronic hemodialysis patients is also demonstrated .
74817
Intervention_Pharmacological
androgen therapy
74818
Intervention_Control
control group
74819
Intervention_Physical
or to
74820
Intervention_Pharmacological
nandrolone decanoate
74821
Intervention_Physical
therapy
74822
Intervention_Pharmacological
androgen therapy
74823
Intervention_Pharmacological
androgen-treated
74824
Intervention_Pharmacological
androgen-treated
74825
Outcome_Physical
anemia
74826
Outcome_Physical
Ferrokinetic and RBC mass determinations
74827
Outcome_Physical
RBC mass
74828
Outcome_Physical
Erythron iron turnover
74829
Outcome_Physical
RBC mass
74830
Outcome_Physical
RBC mass
74831
Outcome_Physical
dialysis-associated blood losses
74832
Outcome_Physical
RBC mass
74833
Outcome_Physical
erythron iron turnover
74834
Outcome_Physical
erythron iron turnovers
74835
Outcome_Adverse-effects
dialysis-associated blood losses
74836
Outcome_Physical
RBC mass
74837
Outcome_Physical
RBC mass
74838
Outcome_Physical
RBC mass
74839
Outcome_Physical
erythron iron turnover
74840
Outcome_Physical
RBC survival
74841
Outcome_Physical
RBC mass
74842
Outcome_Physical
erythron iron turnover
74843
Outcome_Physical
RBC mass
74844
Outcome_Physical
dialysis-associated blood losses
74845
Participant_Condition
anemia
74846
Participant_Condition
chronic renal disease
74847
Participant_Sample-size
4